VIDEO: New data on medullary thyroid cancer at American Thyroid Association Annual Meeting
Click Here to Manage Email Alerts
In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed an update to the ARROW study.
The study, presented at the American Thyroid Association Annual Meeting, evaluated the efficacy and safety of the selective RET inhibitor pralsetinib (Gavreto, Blueprint Medicines) on immunotherapy combinations. "This drug continues to show efficacy and safety," Cabanillas said.
In addition, Cabanillas discussed data on RET M918T somatic mutations. "For a very long time it was thought that the RET M918T, which is the more common mutation in medullary thyroid cancer, conferred a worse, more aggressive disease behavior, and this study did not show that," she said.
Reference:
- Hu M, et al. Oral 45. Presented at: American Thyroid Association Annual Meeting; Oct. 19-23, 2022; Montreal.
- Shirali A, et al. Oral 43. Presented at: American Thyroid Association Annual Meeting; Oct. 19-23, 2022; Montreal.
Collapse
Healio Interviews
Click Here to Manage Email Alerts